COMPASS Pathways
(CMPS)
undefined
undefined%
At close: undefined
4.30
1.78%
After-hours Dec 13, 2024, 04:53 PM EST
Company Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States.
It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.
The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways
| Country | GB |
| IPO Date | Sep 18, 2020 |
| Industry | Medical - Care Facilities |
| Sector | Healthcare |
| Employees | 186 |
| CEO | Kabir Kumar Nath M.A., M.B.A. |
Contact Details
Address: 33 Broadwick Street London, GB | |
| Website | https://compasspathways.com |
Stock Details
| Ticker Symbol | CMPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001816590 |
| CUSIP Number | 20451W101 |
| ISIN Number | US20451W1018 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kabir Kumar Nath M.A., M.B.A. | Chief Executive Officer & Director |
| Anne Benedict | Chief People Officer |
| Dr. Greg Ryslik Ph.D. | Chief Technology Officer |
| Matthew Allen Owens | General Counsel & Chief Legal Officer |
| Teri Loxam M.B.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Christopher Williams | Chief Communications Officer |
| Dr. Guy Goodwin | Chief Medical Officer |
| Dr. Susan C. Stansfield Ph.D. | Advisor |
| Lars Christian Wilde | Senior Advisor |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 25, 2024 | 4 | Filing |
| Oct 25, 2024 | 4 | Filing |
| Oct 18, 2024 | 424B5 | Filing |
| Oct 07, 2024 | S-3 | Filing |
| Sep 27, 2024 | 4 | Filing |
| Sep 27, 2024 | SC 13D/A | [Amend] Filing |